Citius Pharmaceuticals Reports $3.9 Million Revenue in Q1

Written by Emily J. Thompson, Senior Investment Analyst

Updated: Feb 13 2026

0mins

Should l Buy CTXR?

Citius Pharmaceuticals (CTXR) reported business and financial results for the fiscal first quarter ended December 31, 2025, and provided a business update, including progress at its majority-owned subsidiary, Citius Oncology (CTOR). "I am thrilled to report that we have successfully transitioned to a revenue generating company following Citius Oncology's December 2025 launch of Lymphir. We recorded $3.9 million in revenue during the quarter, reflecting the initial sales at Citius Oncology's nationwide network of distributors. This milestone is the result of years of focused execution designed to translate innovation into tangible value for the cutaneous T-cell community and Citius stakeholders alike. I congratulate the entire Citius team on an outstanding effort to bring Lymphirto market," said Leonard Mazur, Chairman and CEO of Citius Oncology and Citius Pharma.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy CTXR?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on CTXR

About CTXR

Citius Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of first-in-class critical care products, with a pipeline of anti-infectives in oncology, adjunct cancer care, stem cell therapy and prescription products. The Company's FDA approved LYMPHIR candidate is a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Its late-stage pipeline also includes Mino-Lok, and CITI-002 (Halo-Lido). Mino-Lok is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections (CRBSIs) and central line associated bloodstream infections (CLABSIs). Halo-Lido is a topical formulation of halobetasol propionate, a corticosteroid, and lidocaine that is intended for the treatment of hemorrhoids. The Company is also seeking to develop and commercialize the NoveCite mesenchymal stem cells (NC-iMSCs) to treat acute respiratory conditions with a near term focus on ARDS.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

LYMPHIR Shows Promise in Gynecologic Cancer Treatment

6 days agoPRnewswire

Clinical Trial Results: The Phase 1 trial led by the University of Pittsburgh demonstrated that LYMPHIR combined with KEYTRUDA showed no unexpected safety signals in 25 patients, indicating a favorable safety profile that could offer new treatment options for difficult-to-treat gynecologic cancers.
Efficacy Assessment: Among 21 evaluable patients, the combination therapy achieved a 24% objective response rate (ORR) and a 48% clinical benefit rate (CBR), highlighting the potential of this combination to enhance anti-tumor activity and warranting further investigation.
Market Potential: LYMPHIR is estimated to have a market potential exceeding $400 million, and as demand for novel therapies increases, Citius Oncology's competitive positioning in oncology will be further strengthened, particularly in the ovarian cancer sector where immunotherapy has had limited impact.
Future Research Plans: Citius Oncology intends to explore the efficacy of LYMPHIR in subsequent Phase 2 studies, and if results are confirmed, it could provide a transformative treatment option for gynecologic cancer patients, significantly improving patient outcomes.

Citius Oncology Reports Positive Phase 1 Trial Results for LYMPHIR in DLBCL

Mar 04 2026PRnewswire

Clinical Trial Response Rate: The LYMPHIR clinical trial conducted at the University of Minnesota and City of Hope demonstrated an 86% overall response rate, including a 57% complete response and a 29% partial response, indicating the potential efficacy of LYMPHIR in patients with high-risk relapsed DLBCL, which may provide new treatment options in the future.
Good Safety Profile: LYMPHIR exhibited a favorable safety profile in the trial, with no dose-limiting toxicities observed, laying a solid foundation for its clinical application and potentially enhancing patient acceptance and adherence to treatment.
Enhancing CAR-T Therapy: The use of LYMPHIR aims to augment the anti-tumor activity of CAR-T cell therapies by improving T-cell depleting effects, which could increase the effectiveness of existing treatment regimens and advance the field of tumor immunotherapy.
Future Research Directions: The findings set the stage for larger clinical trials, with Citius Oncology planning to further explore the combination of LYMPHIR with other therapies to enhance treatment efficacy and improve long-term patient outcomes.

Citius Oncology Reports Positive Phase 1 Trial Results for LYMPHIR in DLBCL

Mar 04 2026Newsfilter

Trial Results: The investigator-initiated study of LYMPHIR™ (E7777) at the University of Minnesota and City of Hope demonstrated an overall response rate (ORR) of 86%, including 57% complete responses (CR) and 29% partial responses (PR), indicating its potential efficacy in high-risk relapsed or refractory diffuse large B-cell lymphoma (DLBCL) patients.
Safety Profile: LYMPHIR was well tolerated in the trial, with no dose-limiting toxicities (DLTs) observed, as all 14 patients completed treatment and proceeded to CAR-T infusion, highlighting its favorable safety profile without any Grade ≥3 immune adverse events reported.
Treg Depletion Effect: A single dose of LYMPHIR resulted in Treg depletion in nearly all patients, with a median reduction of 24 Tregs/µL, suggesting its potential to enhance standard lymphodepletion regimens and improve the anti-tumor activity of CAR-T therapies.
Future Research Directions: These findings set the stage for larger studies to assess the potential of LYMPHIR to enhance CAR-T efficacy through prolonged use, further advancing Citius Oncology's strategic positioning in the field of cancer immunotherapy.